Triomics raises $15M Series A to automate cancer clinical trials matching
Summary
However, busy oncologists and nurses often lack the time to learn about all the clinical trials that may be right for their patients.I am not a doctor, so I dont know about the day-to-day challenges of oncology medical staff. But due to a shortage of oncology professionals, many cancer patients arent offered to participate or they miss their eligibility window.Triomics was founded by former MIT biotech researcher Sarim Khan and AI scientist at Adobe Hrituraj Singh. The pair, who have been friends since college, decided to build Triomics in 2021 after realizing that advances in generative AI and LLMs could help extract data from electronic health records (EHR) to help find appropriate clinical trials for cancer patients in minutes instead of hours.Khan and Singh entered Y Combinator in the winter of 2021 and proceeded to work on an LLM built specifically for cancer centers and oncology departments in hospital systems.Three years later, Triomics says six cancer centers and hospitals are actively using or piloting its LLM, and it plans to double that number by the end of the year. And now the company has raised a $15 million Series A from Lightspeed, Nexus Venture Partners, General Catalyst and Y Combinator to help it continue to develop its platform and roll it out to new customers.While reducing how long it takes for patients to be matched with clinical trials may seem like the most immediately valuable application of Triomics software, Khan says that Triomics is a lot more than a clinical trials company. Doctors use it for several different use cases that I could just go on and on about, he said.After Triomics LLM, which the company is calling OncoLLM, reads the patients medical record, the data could be used to help prepare doctors and other medical staff for patient visits or to help submit cancer data with details of organs affected and stage of progressions to state regulatory agencies.Of course, Triomics isnt alone in tackling this area.